Spots Global Cancer Trial Database for Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
Official Title: A Phase II Trial of Pemetrexed in Combination With Gemcitabine as First Line Treatment in Extensive-Stage Small Cell Lung Carcinoma
Study ID: NCT00129974
Conditions
Interventions
Study Description
Brief Summary: The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer. The second purpose is to see if the side effects appear better than what is expected with standard chemotherapy.
Detailed Description: Extensive-stage small cell lung carcinoma is incurable. Present therapies are toxic and responses are short lived. This phase II, single arm, window of opportunity study will assess the response rate and toxicity of pemetrexed and gemcitabine in this cohort.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tufts-New England Medical Center, Boston, Massachusetts, United States
Commonwealth Hematology/Oncology, Quincy, Massachusetts, United States
Baystate Medical Center, Springfield, Massachusetts, United States
Contact Details
Name: John R Goffin, MD FRCPC
Affiliation: Tufts Medical Center
Role: PRINCIPAL_INVESTIGATOR
Name: John McCann, MD
Affiliation: Baystate Medical Center
Role: PRINCIPAL_INVESTIGATOR
Name: Walter A Kagan, MD PhD
Affiliation: Commonwealth Hematology/Oncology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
